Skip to main content
SpringerLink
Log in

Lung Cancer in Older Adults: Systemic Treatment

  • Living reference work entry
  • First Online:
Geriatric Oncology

Abstract

Lung cancer is the first cause of death by cancer throughout the entire world. Its incidence increases with age, and thus median age at diagnosis is 70 years in the USA.

As in younger counterparts, non-small cell lung cancer represents 85% of the cases, but squamous cell carcinoma is more frequent than in younger patients. Diagnosis is often performed at an advanced stage, and thus systemic treatment is frequently to be discussed. It is only since two decades that clinical trials devoted to elderly patients have been conducted, and until recently, treatment was often suboptimal, with poor results which contributed to nihilistic attitudes among patients, relatives, and doctors.

Regarding small cell lung cancer, the doublet carboplatin-etoposide is the most frequently used in elderly patients. For non-small cell lung cancer, targeted therapies should be used in those patients with EGFR or V600E BRAF mutations and ALK or ROS1 translocations whatever the performance status (PS). For patients without targetable mutations, carboplatin-based doublet can be used as frontline therapy in patients with PS 0–2. Regarding second-line therapy, the most frequently studied in elderly patients has been erlotinib. The role of checkpoint inhibitors in elderly patients is still not well established as the only data we have are subgroup analyses of phase III randomized trials with no age upper limit and with no specific clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abe T, Takeda K, Ohe Y, et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015;33:575–81.

    Article  CAS  PubMed  Google Scholar 

  • Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e1S–e29S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ansari RH, Socinski MA, Edelman MJ, et al. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 2011;78:162–71.

    Article  PubMed  Google Scholar 

  • Ardizzoni A, Favaretto A, Boni L, et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis – a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol. 2005;23:569–75.

    Article  CAS  PubMed  Google Scholar 

  • Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.

    Article  CAS  PubMed  Google Scholar 

  • Azzoli CG, Temin S, Aliff T, et al. Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29:3825–31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Balducci L, Carreca I. The role of myelopoietic growth factors in managing cancer in the elderly. Drugs. 2002;62(Suppl 1):47–63.

    Article  CAS  PubMed  Google Scholar 

  • Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–37.

    Article  CAS  PubMed  Google Scholar 

  • Barlesi F, Mazieres J, Merlio J-P, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387:1415–26.

    Article  CAS  PubMed  Google Scholar 

  • Belani CP, Lee JS, Socinski MA et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005a;16(7):1069–75

    Article  CAS  PubMed  Google Scholar 

  • Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005b;104:2766–74.

    Article  CAS  PubMed  Google Scholar 

  • Blanchard EM, Moon J, Hesketh PJ, et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011;6:115–20.

    Article  PubMed  PubMed Central  Google Scholar 

  • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;2:CD011430.

    Google Scholar 

  • Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol. 2013;8:1272–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chawla N, Yabroff KR, Mariotto A, McNeel TS, Schrag D, Warren JL. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Ann Epidemiol. 2014;24:666–672.e2.

    Article  PubMed  PubMed Central  Google Scholar 

  • Corre R, Greillier L, Le Caer H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol. 2016;34:1476–83.

    Article  CAS  PubMed  Google Scholar 

  • Eba J, Shimokawa T, Nakamura K, et al. A phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201). Jpn J Clin Oncol. 2015;45:115–8.

    Article  PubMed  Google Scholar 

  • Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter? Cancer Treat Rev. 2017;60:60–8.

    Article  CAS  PubMed  Google Scholar 

  • Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:2529–36.

    Article  CAS  PubMed  Google Scholar 

  • Fruh M, Rolland E, Pignon JP, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol. 2008;26:3573–81.

    Article  CAS  PubMed  Google Scholar 

  • Fukuda M, Soda H, Soejima Y, et al. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2006;58:601–6.

    Article  CAS  PubMed  Google Scholar 

  • Ganti AK, de Shazo M, Weir AB 3rd, Hurria A. Treatment of non-small cell lung cancer in the older patient. J Natl Compr Cancer Netw. 2012;10:230–9.

    Article  CAS  Google Scholar 

  • Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist. 2001;6(Suppl 1):4–7.

    Article  CAS  PubMed  Google Scholar 

  • Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72.

    Article  CAS  PubMed  Google Scholar 

  • Gridelli C, de Marinis F, Thomas M, et al. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. J Thorac Oncol. 2014;9:991–7.

    Article  CAS  PubMed  Google Scholar 

  • Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13:e437–44.

    Article  PubMed  Google Scholar 

  • Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3484–515.

    Article  PubMed  Google Scholar 

  • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.

    Article  CAS  PubMed  Google Scholar 

  • Inoue Y, Inui N, Asada K, et al. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemother Pharmacol. 2015;76:155–61.

    Article  CAS  PubMed  Google Scholar 

  • Jalal SI, Riggs HD, Melnyk A, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol. 2012;23:1730–8.

    Article  CAS  PubMed  Google Scholar 

  • Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e400S–19S.

    Article  CAS  PubMed  Google Scholar 

  • Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63.

    Article  CAS  PubMed  Google Scholar 

  • Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173–81.

    Article  PubMed  Google Scholar 

  • Larive S, Bombaron P, Riou R, et al. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer. 2002;35:1–7.

    Article  CAS  PubMed  Google Scholar 

  • Laskin J, Crinò L, Felip E, et al. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol. 2012;7:203–11.

    Article  CAS  PubMed  Google Scholar 

  • Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249–57.

    Article  PubMed  Google Scholar 

  • Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol. 2010;5:1970–6.

    Article  PubMed  Google Scholar 

  • Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23:190–6. https://doi.org/10.1200/JCO.2005.07.172.

    Article  PubMed  CAS  Google Scholar 

  • Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;23:6865–72.

    Article  PubMed  Google Scholar 

  • Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488–515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mellemgaard A, Luchtenborg M, Iachina M, et al. Role of comorbidity on survival after radiotherapy and chemotherapy for nonsurgically treated lung cancer. J Thorac Oncol. 2015;10:272–9.

    Article  CAS  PubMed  Google Scholar 

  • Minuti G, D’Incecco A, Cappuzzo F. Current and emerging options in the management of EGFR mutation-positive non-small-cell lung cancer: considerations in the elderly. Drugs Aging. 2015;32:907–16.

    Article  CAS  PubMed  Google Scholar 

  • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.

    Article  Google Scholar 

  • Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97:162–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pallis AG, Gridelli C, van Meerbeeck JP, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010a;21:692–706.

    Article  CAS  PubMed  Google Scholar 

  • Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in elderly patients. Cancer. 2010b;116:1192–200.

    Article  CAS  PubMed  Google Scholar 

  • Pisters KMW, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25:5506–18.

    Article  PubMed  Google Scholar 

  • Quoix E, Breton JL, Daniel C, et al. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol. 2001;12:957–62.

    Article  CAS  PubMed  Google Scholar 

  • Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88.

    Article  CAS  PubMed  Google Scholar 

  • Quoix E, Westeel V, Moreau L, et al. Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. Eur Respir J. 2014;43:240–9.

    Article  CAS  PubMed  Google Scholar 

  • Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5.

    Article  CAS  PubMed  Google Scholar 

  • Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502.

    Article  PubMed  Google Scholar 

  • Sacher AG, Le LW, Leighl NB, Coate LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol. 2013;8:366–8.

    Article  PubMed  Google Scholar 

  • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.

    Article  CAS  PubMed  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.

    Article  CAS  PubMed  Google Scholar 

  • Siegel R, Naishadham D, Jemal A. CA Cancer J Clin. 2012;62:10–29.

    Article  Google Scholar 

  • Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One. 2014;9:e115060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Souhami RL, Spiro SG, Rudd RM, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89:577–80.

    Article  CAS  PubMed  Google Scholar 

  • Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626–31.

    Article  PubMed  Google Scholar 

  • Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013;18:573–83.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tsukada H, Yokoyama A, Goto K, et al. Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207dagger. Jpn J Clin Oncol. 2015;45:88–95.

    Article  PubMed  Google Scholar 

  • Wang S, Wong M, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30:1447–55.

    Article  PubMed  PubMed Central  Google Scholar 

  • Westeel V, Murray N, Gelmon K, et al. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol. 1998;16:1940–7.

    Article  CAS  PubMed  Google Scholar 

  • Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:2350–7.

    Article  CAS  PubMed  Google Scholar 

  • Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000;89:1953–60.

    Article  CAS  PubMed  Google Scholar 

  • Zukin M, Barrios CH, Pereira JR, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013;31:2849–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Diseases, Nouvel Hôpital Civil, University Hospital, Strasbourg, France

    Elisabeth Quoix

Authors
  1. Elisabeth Quoix
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisabeth Quoix .

Editor information

Editors and Affiliations

  1. Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, Florida, USA

    Martine Extermann

Section Editor information

  1. Department of Medical Oncology, Institute Curie, Hôpital René Huguenin, Saint-Cloud, France

    Etienne Brain

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Quoix, E. (2018). Lung Cancer in Older Adults: Systemic Treatment. In: Extermann, M. (eds) Geriatric Oncology . Springer, Cham. https://doi.org/10.1007/978-3-319-44870-1_31-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44870-1_31-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44870-1

  • Online ISBN: 978-3-319-44870-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation